• 28 Apr 2026
• Admin
• News Article

Alembic Pharmaceuticals Secures USFDA Approval for Fingolimod Capsules

Alembic Pharmaceuticals Limited has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for fingolimod capsules, 0.5 mg.

The approval strengthens Alembic’s position in the competitive US generics market—particularly in the high-value central nervous system (CNS) segment.

What the Approval Covers?

Alembic’s fingolimod capsules are therapeutically equivalent to the reference listed drug (RLD), Gilenya, developed by Novartis Pharmaceuticals Corporation.

Key Details

• Dosage: 0.5 mg capsules
• Regulatory pathway: ANDA (generic approval)
• Reference drug: Gilenya

This means Alembic can market a generic version with the same safety, efficacy, and quality profile as the branded drug.

Indication: Multiple Sclerosis

Fingolimod is a sphingosine 1-phosphate (S1P) receptor modulator used to treat relapsing forms of Multiple Sclerosis.

Approved Use Includes

• Clinically isolated syndrome
• Relapsing-remitting multiple sclerosis (RRMS)
• Active secondary progressive disease

It is approved for patients aged 10 years and older.

Mechanism of Action

Fingolimod works by:

• Modulating S1P receptors
• Preventing lymphocytes from exiting lymph nodes
• Reducing immune-mediated damage to the central nervous system

This helps lower relapse rates and slow disease progression in MS patients.

Strategic Significance for Alembic

This approval is more than just another addition to Alembic’s portfolio. It reflects a targeted push into complex generics.

Why It Matters

• CNS drugs like fingolimod are technically challenging to develop
• Generic competition in MS therapies remains limited compared to other categories
• Strong commercial potential in the US market

Alembic now has:

• 237 total ANDA approvals
  • 219 final approvals
  • 18 tentative approvals

This scale reinforces its growing footprint in regulated markets.

Market Context: Post-Exclusivity Opportunity

Gilenya was one of the first oral disease-modifying therapies for MS, generating significant global revenue for Novartis. With patent expiries, the market has opened up for generics:

• Increased competition is expected
• Pricing pressure on branded therapies will intensify
• Patient access is likely to improve

Alembic’s entry positions it to capture a share of this transition phase.

Bigger Industry Trend: Complex Generics as Growth Drivers

The approval highlights a broader shift across Indian pharma companies:

• Moving beyond simple generics into complex formulations
• Targeting high-barrier therapeutic areas like CNS and oncology
• Leveraging regulatory experience in the US market

For companies like Alembic, success in these segments requires:

• Strong R&D capabilities
• Regulatory expertise
• Manufacturing precision

Final Takeaway

Alembic’s USFDA approval for fingolimod capsules marks a strategic step into high-value CNS generics.

For the company, it delivers:

• Entry into the MS treatment market
• Expansion of its US generics portfolio
• Reinforcement of its R&D-driven growth strategy

For the market, it signals continued momentum toward more accessible MS therapies as generics enter post-patent landscapes.